Sugi Predict

Sugi Predict / Compounds / SCHEMBL3579523

SCHEMBL3579523

SCHEMBL3579523

CNc1ccsc1C(=O)OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.65
▸ HPGD P15428 5/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ NPSR1 Q6W5P4 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ LMNA P02545 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ MAPK10 P53779 2/20 0.58
▸ MAPT P10636 2/20 0.58
▸ KMT2A Q03164 3/20 0.56
▸ POLB P06746 2/20 0.56
▸ PKM P14618 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ GLA P06280 1/20 0.56
▸ MEN1 O00255 2/20 0.55
▸ GAA P10253 1/20 0.55
▸ TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15846889 0.85 NPC1 (0.65) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL2430838 0.84 NPC1 (0.59) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL538048 0.83 NPC1 (0.63) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL4956852 0.83 NPC1 (0.63) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL9396711 0.82 PKM (0.67) NPC1HPGDSMN1; SMN2L3MBTL1MAPT
SCHEMBL1367369 0.81 NPC1 (0.71) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL2799189 0.80 NPC1 (0.59) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL27884041 0.80 NPC1 (0.59) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL995011 0.80 NPC1 (0.69) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1
SCHEMBL9410725 0.80 NPC1 (0.59) NPC1HPGDSMN1; SMN2L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 — — EP disclosed
CN-110914242-B Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2023-07-25 — — CN disclosed
EP-3615022-B1 SMALL ORGANIC MOLECULES FOR USE IN THE TREATMENT OF NEUROINFLAMMATORY DISORDERS MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND TEL AVIV MEDICAL CT (IL) 2023-06-07 — — EP disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 — — EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 — — US disclosed
EP-3151669-B1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-10-28 — — EP disclosed
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-09-10 — — US disclosed
CN-110914242-A Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2020-03-24 — — CN disclosed
EP-3615514-A2 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF Aviara Pharmaceuticals, Inc. (US) 2020-03-04 — — EP disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 — — US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 — — US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 — — US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 — — US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 — — US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 — — WO disclosed
US-5342843-A Bronchodilators, immunoregulators KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-08-30 — — US disclosed
EP-0579836-A1 THIENOIMIDAZOPYRIDONE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-01-26 — — EP disclosed
CN-86104822-A The preparation method of therapeutical agent — 1987-12-23 — — CN disclosed
US-4710506-A Antihypertensive thienopyridines THE BOOTS COMPANY PLC (GB) 1987-12-01 — — US disclosed
EP-0209977-A2 Thienopyridones, processes and intermediates for their preparation and pharmaceutical compositions containing them The Boots Company PLC (GB) 1987-01-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 NPC1 3297/4885HPGD 1373/4885SMN1; SMN2 2021/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A NPC1 4158/4885HPGD 381/4885SMN1; SMN2 3054/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 NPC1 3297/4885HPGD 1373/4885SMN1; SMN2 2021/4885
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 NPC1 2259/4885HPGD 650/4885SMN1; SMN2 3626/4885
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A NPC1 4158/4885HPGD 381/4885SMN1; SMN2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.